About Geneservice

Geneservice make available genomic and proteomic libraries from a wide range of organisms in various formats (e.g. single clones, plates, pools, and high density filters) including the Mammalian Genome Collection (MGC) and IMAGE clones; and more recently RNAi libraries. Geneservice have invested in the latest genetic and genomic technologies so that you don't have to. Why invest in hardware, maintenance and training; only to discover that you've selected the wrong technology? We have the latest high-throughput hardware, managed by experts and this gives you the best in quality, turnaround times and pricing. Geneservice are a one-stop-shop for your gene discovery projects. Services include Whole Genome Amplification, DNA sequencing, microsatellite and SNP genotyping including 10K and 100K SNP mapping, and expression array analysis. There are currently about 30 staff at Geneservice. We have an experienced management team and a scientific team with wide-ranging genomic biology experience to help facilitate your project cost effectively.   Current Group Photo

Company Directors

Tom Weaver is the Managing Director of Geneservice and was the Chief Executive of MRC geneservice (MRCg), the not-for-profit genomic biological resource centre and contract service provider which was part of the UK Medical Research Council. From 1998 he was Director of Technology Development for Incyte Genomics in Cambridge, UK, where his team developed high-throughput methods for mutation detection and genotyping in Mouse and Human. From 1996 he was Head of Biology at Hexagen Ltd, a functional genomics start up company from the University of Cambridge dept of Genetics. Prior to this he was a post-doctoral research fellow at the University of Cambridge and MRC Lab of Molecular Biology. He received his PhD from the University of Wisconsin in the United States in 1990. Dr. Weaver is also on the scientific advisory boards of the Cambridge Genetic Knowledge Park, SmartBead Technology, and the UK BioIndustry Associations panel on Bioinformatics.

Roger is a widely experienced, commercially orientated Finance professional. Roger previously developed the commercial infrastructure and systems at MRCg and built the commercial team. Prior to joining MRCg Roger was both a consultant and finance director primarily in the Biotech and Pharmaceutical sector. In particular he was Finance Director of MolecularNature Ltd (a BBSRC spin out) and founding FD of Oxford BioMedica (an Oxford University spin out) when it was floated on AIM. Earlier in his career he was Finance Director of Evans Medical (now Celltech Medeva) and a manager with KPMG in London.

Nick is the Operations Director of Geneservice and played a similar role as the Chief Operating Officer at MRCg. Nick is responsible for all the customer facing operations of the organisation. Previously, Nick developed a DNA sequencing service for MRCg and made it a profitable concern whilst jointly working in the business development team. Before that Nick worked for 4 years as DNA sequencing production manager on high-throughput projects for the MRC, and worked for 5 years on the complex genetics of Asthma and Eczema at Oxford University. Originally, Nick qualified as a microbiologist and worked in the NHS. It was here that he completed a PhD in 1995 on the molecular methods used to characterise meningitis outbreaks whilst also considering the impact of the HIB meningitis vaccine that has now been introduced UK-wide.

Andy Richards joined Geneservice as Chairman in November 2005. He brings to the company experience as a serial Biotechnology entrepreneur and business angel. He is currently a director of Vectura plc, Biowisdom, Daniolabs, Theradeas, Cancer Research Technology Ltd (commercial arm of CR-UK) and Babraham Bioscience Technology Ltd. He was a founder of Chiroscience in 1992 and an executive director through to the merger with Celltech in August 1999. Since that time he has been founding and investing in new biotechnology companies including several of those listed above as well as Arakis, Cambridge Biotechnology Ltd, Amedis Pharmaceuticals and Sirus Pharmaceuticals all of which were recently sold. Prior to founding Chiroscience he was at ICI (now Zeneca) and PA Consulting. He is a Cambridge graduate with a PhD in Enzyme Chemistry. He is a founder member of the Cambridge Angels, a founder investor in LibraryHouse, a member of the Council of UEA and a director of the Bioindustry Association (BIA)